Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
Fingolimod (FTY720) stimulates ca(2+)/calcineurin signaling in fission yeast.
Biologic therapies: lessons from multiple sclerosis.
Daily hassles reported by Dutch multiple sclerosis patients.
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration.
Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.
A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation.
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Efficient transdifferentiation of human adipose-derived stem cells into Schwann-like cells: A promise for treatment of demyelinating diseases.
[Differential diagnosis of late-stage neuroborreliosis with affection of the central nervous system.]
Are there Epstein-Barr virus seronegative patients with multiple sclerosis?
First patient enrolled in third Phase III study of oral laquinimod for relapsing-remitting multiple sclerosis
FTY720 is neuroprotective after cuprizone-induced central nervous system demyelination.
Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin.
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.
Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain.
Sarcoidosis Triggered by Interferon-Beta Treatment of Multiple Sclerosis: A Case Report and Focused Literature Review.
1st International Symposium on Gait and Balance in MS: Gait and Balance Measures in the Evaluation of People with MS.
Psychiatric symptoms in patients with multiple sclerosis.
Substance Name: MEDI 551
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Pages
« first
‹ previous
…
207
208
209
210
211
212
213
214
215
…
next ›
last »